BUZZ-Legend Biotech up as Q2 sales for J&J-partnered blood cancer therapy rises

Reuters

Jul 16, 2025

BUZZ-Legend Biotech up as <a href="https://laohu8.com/S/QTWO">Q2</a> sales for J&J-partnered blood cancer therapy rises

** Shares of cancer therapy maker Legend Biotech LEGN.O rise 4.2% to $41.25 premarket

** Partner Johnson & Johnson JNJ.N reports Q2 sales of blood cancer cell therapy Carvykti of $439 mln vs consensus estimates of $419 mln

** JNJ says Carvykti increase is driven by continued share gains and capacity expansion

** "We look to continued growth in 2H25, and expect revenue to accelerate given a typically strong back half, especially with additional production likely to come online,"- brokerage RBC Capital Markets

** We like that Carvykti continues to grow at ~19% quarter over quarter, suggesting there is still untapped demand in the myeloma market, which can enable further growth in 2H25 and 2026, brokerage says

** Up to last close, LEGN up 21.7% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2551288128"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551288128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551288128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551288128","market":"nz","top_or_hot":-1,"title":"BUZZ-Legend Biotech up as Q2 sales for J&J-partnered blood cancer therapy rises","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Legend Biotech up as <a href=\"https://laohu8.com/S/QTWO\">Q2</a> sales for J&amp;J-partnered blood cancer therapy rises </title></head><body><p>** Shares of cancer therapy maker Legend Biotech <span>LEGN.O</span> rise 4.2% to $41.25 premarket </p><p>** Partner Johnson &amp; Johnson <span><a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.N</span> reports Q2 sales of blood cancer cell therapy Carvykti of $439 mln vs consensus estimates of $419 mln</p><p>** JNJ says Carvykti increase is driven by continued share gains and capacity expansion</p><p>** \"We look to continued growth in 2H25, and expect revenue to accelerate given a typically strong back half, especially with additional production likely to come online,\"- brokerage RBC Capital Markets</p><p>** We like that Carvykti continues to grow at ~19% quarter over quarter, suggesting there is still untapped demand in the myeloma market, which can enable further growth in 2H25 and 2026, brokerage says </p><p>** Up to last close, LEGN up 21.7% YTD </p><p> (Reporting by Sneha S <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>)</p><p> ((Sneha.SK@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Legend Biotech up as Q2 sales for J&J-partnered blood cancer therapy rises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Legend Biotech up as Q2 sales for J&J-partnered blood cancer therapy rises\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-16 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Legend Biotech up as <a href=\"https://laohu8.com/S/QTWO\">Q2</a> sales for J&amp;J-partnered blood cancer therapy rises </title></head><body><p>** Shares of cancer therapy maker Legend Biotech <span>LEGN.O</span> rise 4.2% to $41.25 premarket </p><p>** Partner Johnson &amp; Johnson <span><a href=\"https://laohu8.com/S/JNJ\">JNJ</a>.N</span> reports Q2 sales of blood cancer cell therapy Carvykti of $439 mln vs consensus estimates of $419 mln</p><p>** JNJ says Carvykti increase is driven by continued share gains and capacity expansion</p><p>** \"We look to continued growth in 2H25, and expect revenue to accelerate given a typically strong back half, especially with additional production likely to come online,\"- brokerage RBC Capital Markets</p><p>** We like that Carvykti continues to grow at ~19% quarter over quarter, suggesting there is still untapped demand in the myeloma market, which can enable further growth in 2H25 and 2026, brokerage says </p><p>** Up to last close, LEGN up 21.7% YTD </p><p> (Reporting by Sneha S <a href=\"https://laohu8.com/S/TKKD.SI\">K</a>)</p><p> ((Sneha.SK@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nL6N3TD0HU:1","article_id":"2551288128","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551288128","pubTimestamp":1752669281,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Legend Biotech up as Q2 sales for J&J-partnered blood cancer therapy rises** Shares of cancer therapy maker Legend Biotech LEGN.O rise 4.2% to $41.25 premarket ** Partner Johnson & Johnson JNJ.N reports Q2 sales of blood cancer cell therapy Carvykti of $439 mln vs consensus estimates of $419 mln** JNJ says Carvykti increase is driven by continued share gains and capacity expansion** \"We look to continued growth in 2H25, and expect revenue to accelerate given a typically strong back half, especially with additional production likely to come online,\"- brokerage RBC Capital Markets** We like that Carvykti continues to grow at ~19% quarter over quarter, suggesting there is still untapped demand in the myeloma market, which can enable further growth in 2H25 and 2026, brokerage says ** Up to last close, LEGN up 21.7% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生","LEGN":"传奇生物","01548":"金斯瑞生物科技"},"translate_title":"BUZZ-Legend Biotech与强生合作的血癌疗法第二季度销售额上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":0.9,"01548":0.9,"JNJ":0.9},"content_text":"BUZZ-Legend Biotech up as Q2 sales for J&J-partnered blood cancer therapy rises ** Shares of cancer therapy maker Legend Biotech LEGN.O rise 4.2% to $41.25 premarket ** Partner Johnson & Johnson JNJ.N reports Q2 sales of blood cancer cell therapy Carvykti of $439 mln vs consensus estimates of $419 mln** JNJ says Carvykti increase is driven by continued share gains and capacity expansion** \"We look to continued growth in 2H25, and expect revenue to accelerate given a typically strong back half, especially with additional production likely to come online,\"- brokerage RBC Capital Markets** We like that Carvykti continues to grow at ~19% quarter over quarter, suggesting there is still untapped demand in the myeloma market, which can enable further growth in 2H25 and 2026, brokerage says ** Up to last close, LEGN up 21.7% YTD  (Reporting by Sneha S K) ((Sneha.SK@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}